Andriy Krendyukov

Andriy Krendyukov

Heidelberg, BW 69120, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

Journal: EClinicalMedicine

Published: April 26, 2024

A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.

A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: February 24, 2023

Medical Affairs and Innovative Medicinal Product Strategy Development.

Medical Affairs and Innovative Medicinal Product Strategy Development.

Journal: Pharmaceutical medicine

Published: February 16, 2022

Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.

Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.

Journal: Frontiers in oncology

Published: May 25, 2021

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence.

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence.

Journal: Cancer management and research

Published: December 18, 2020

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.

Journal: Frontiers in oncology

Published: December 01, 2020

Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives.

Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives.

Journal: Pharmaceutical medicine

Published: June 20, 2020

Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities.

Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities.

Journal: Frontiers in oncology

Published: June 06, 2020

Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology.

Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology.

Journal: Pharmaceutical medicine

Published: February 29, 2020

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: August 24, 2019

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.

Journal: Journal of neuro-oncology

Published: August 22, 2019

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.

Journal: Journal of medical economics

Published: August 22, 2019

Showing 1-12 of 44

Last Updated: 09/26/2026